{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:28:46Z","timestamp":1790494126382,"version":"4.1.0"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0016532","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T22:06:05Z","timestamp":1296165965000},"page":"e16532","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Mucosal Targeting of a BoNT\/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT\/A Neutralizing Antibodies in Rabbits"],"prefix":"10.1371","volume":"6","author":[{"given":"Herman F.","family":"Staats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Fielhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afton L.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice A.","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soman N.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity.","volume":"5","author":"DB Lacy","year":"1998","journal-title":"Nature Structural Biology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01891992","article-title":"Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains.","volume":"13","author":"KG Krieglstein","year":"1994","journal-title":"Journal of Protein Chemistry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-5793(00)01954-2","article-title":"Structure-based sequence alignment for the Beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site.","volume":"482","author":"K Ginalski","year":"2000","journal-title":"FEBS Letters"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum Toxin as a Biological Weapon: Medical and Public Health Management.","volume":"285","author":"SS Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention.","volume":"27","author":"LA Smith","year":"2009","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: Past history and recent developments.","volume":"5","author":"JM Rusnak","year":"2009","journal-title":"Hum Vaccin"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.4049\/jimmunol.177.8.5524","article-title":"Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A.","volume":"177","author":"M Maddaloni","year":"2006","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-3083.1997.d01-159.x","article-title":"Nasal lymphoid tissue (NALT) as a mucosal immune inductive site.","volume":"46","author":"HY Wu","year":"1997","journal-title":"Scandinavian Journal of Immunology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02786362","article-title":"Nasal Lymphoid Tissue, Intranasal Immunization, and Compartmentalization of the Common Mucosal Immune System.","volume":"16","author":"HY Wu","year":"1997","journal-title":"Immunologic Research"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/1521-4141(200211)32:11<3191::AID-IMMU3191>3.0.CO;2-0","article-title":"Structural and functional differences between putative mucosal inductive sites of the rat.","volume":"32","author":"AW Zuercher","year":"2002","journal-title":"European Journal of Immunology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.0105-2896.2005.00299.x","article-title":"Bronchus- and nasal-associated lymphoid tissues.","volume":"206","author":"J Bienenstock","year":"2005","journal-title":"Immunological Reviews"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer&apos;s-patch-mediated mucosal immunity.","volume":"4","author":"H Kiyono","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2249.2003.02311.x","article-title":"Nasal-associated lymphoid tissue (NALT): frequency and localization in young children.","volume":"134","author":"AS Debertin","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.vetimm.2009.08.011","article-title":"NALT (nasal cavity-associated lymphoid tissue) in the rabbit.","volume":"133","author":"C Casteleyn","year":"2010","journal-title":"Vet Immunol Immunopathol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.ijporl.2003.08.018","article-title":"Immunology of tonsils and adenoids: everything the ENT surgeon needs to know.","volume":"67","author":"P Brandtzaeg","year":"2003","journal-title":"International Journal of Pediatric Otorhinolaryngology"},{"key":"ref16","first-page":"2023","article-title":"Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils.","volume":"157","author":"PN Boyaka","year":"2000","journal-title":"Am J Pathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: a new class of highly effective vaccine adjuvants.","volume":"14","author":"JB McLachlan","year":"2008","journal-title":"Nature Medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1016\/j.vaccine.2009.03.069","article-title":"The mast cell activator compound 48\/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.","volume":"27","author":"AL McGowen","year":"2009","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.153.2.647","article-title":"Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin.","volume":"153","author":"DP Snider","year":"1994","journal-title":"Journal of Immunology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.165.9.4778","article-title":"Cutting Edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.","volume":"165","author":"FW van Ginkel","year":"2000","journal-title":"The Journal of Immunology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.4049\/jimmunol.155.10.4621","article-title":"Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.","volume":"155","author":"M Marinaro","year":"1995","journal-title":"Journal of Immunology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.68.2.672-679.2000","article-title":"Mucosally Induced Immunoglobulin E-Associated Inflammation in the Respiratory Tract.","volume":"68","author":"JW Simecka","year":"2000","journal-title":"Infect Immun"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMp048006","article-title":"Nasal vaccination, Escherichia coli enterotoxin, and Bell&apos;s palsy. [comment].","volume":"350","author":"RB Couch","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell&apos;s palsy in Switzerland. [see comment].","volume":"350","author":"M Mutsch","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell&apos;s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.","volume":"4","author":"DJ Lewis","year":"2009","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.","volume":"75","author":"HF Staats","year":"2007","journal-title":"Infect Immun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2006.22.558","article-title":"Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines.","volume":"22","author":"SK Nordone","year":"2006","journal-title":"AIDS Research and Human Retroviruses"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.76.2.517-524.2002","article-title":"Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization.","volume":"76","author":"CP Bradney","year":"2002","journal-title":"J Virol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/088922202760072348","article-title":"Epidermal Powder Immunization with a Recombinant HIV gp120 Targets Langerhans Cells and Induces Enhanced Immune Responses.","volume":"18","author":"D Chen","year":"2002","journal-title":"AIDS Research and Human Retroviruses"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1128\/JVI.76.6.2835-2847.2002","article-title":"Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.","volume":"76","author":"IK Srivastava","year":"2002","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-1759(97)00059-8","article-title":"Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA).","volume":"205","author":"N McCloskey","year":"1997","journal-title":"Journal of Immunological Methods"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.","volume":"73","author":"MR Baldwin","year":"2005","journal-title":"Infection & Immunity"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future.","volume":"27","author":"LA Smith","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0041-0101(89)90202-X","article-title":"Molecular differences between type A botulinum neurotoxin and its toxoid.","volume":"27","author":"BR Singh","year":"1989","journal-title":"Toxicon"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3181\/00379727-135-35008","article-title":"Botulinal toxin and toxoid as antigens.","volume":"135","author":"RC Heimsch","year":"1970","journal-title":"Proceedings of the Society for Experimental Biology & Medicine"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/viro.2000.0285","article-title":"Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.","volume":"272","author":"W Olszewska","year":"2000","journal-title":"Virology"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20023","article-title":"Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.","volume":"19","author":"JD Marks","year":"2004","journal-title":"Movement Disorders"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt0602-597","article-title":"Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.","volume":"20","author":"JA Maynard","year":"2002","journal-title":"Nature Biotechnology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/heapro\/dah110","article-title":"Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses.","volume":"19","author":"M Kermode","year":"2004","journal-title":"Health Promot Int"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0195-6701(07)60027-9","article-title":"The First Global Patient Safety Challenge \u201cClean Care is Safer Care\u201d: from launch to current progress and achievements.","volume":"65","author":"B Allegranzi","year":"2007","journal-title":"Journal of Hospital Infection"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1258\/ijsa.2008.008441","article-title":"Increase in clinical prevalence of AIDS implies increase in unsafe medical injections.","volume":"20","author":"S Reid","year":"2009","journal-title":"Int J STD AIDS"},{"key":"ref42","article-title":"Fact Sheet 231.","year":"2002"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0264-410X(00)00358-3","article-title":"Ensuring vaccine safety in immunization programmes\u2014a WHO perspective.","volume":"19","author":"L Jodar","year":"2001","journal-title":"Vaccine"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.2003.68.341","article-title":"Fear of injections in young adults: prevalence and associations.","volume":"68","author":"Y Nir","year":"2003","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0264-410X(96)00175-2","article-title":"Intranasal Booster Vaccination Against Diphtheria and Tetanus in Man.","volume":"15","author":"H Aggerbeck","year":"1997","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/SMJ.0b013e3181eda3d5","article-title":"Influenza vaccination acceptance and refusal rates among health care personnel.","volume":"103","author":"VS Millner","year":"2010","journal-title":"Southern Medical Journal"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0264-410X(01)00471-6","article-title":"Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. [see comment].","volume":"20","author":"WE Beyer","year":"2002","journal-title":"Vaccine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.","volume":"59","author":"RJ Cox","year":"2004","journal-title":"Scandinavian Journal of Immunology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1016\/j.vaccine.2006.12.001","article-title":"Induction of secretory immunity and memory at mucosal surfaces.","volume":"25","author":"P Brandtzaeg","year":"2007","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2010.08.006","article-title":"Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.","volume":"28","author":"WM Gwinn","year":"2010","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nmat2784","article-title":"Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.","volume":"9","author":"T Nochi","year":"2010","journal-title":"Nat Mater"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1128\/JVI.79.18.11627-11637.2005","article-title":"Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.","volume":"79","author":"JW Schoggins","year":"2005","journal-title":"Journal of Virology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/IAI.71.1.275-286.2003","article-title":"Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.","volume":"71","author":"SL Harris","year":"2003","journal-title":"Infect Immun"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/IAI.70.2.584-590.2002","article-title":"Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.","volume":"70","author":"CL Vermont","year":"2002","journal-title":"Infect Immun"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.1992.03480110065035","article-title":"Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.","volume":"267","author":"Y Schlesinger","year":"1992","journal-title":"Jama"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.76.2.517-524.2002","article-title":"Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.","volume":"76","author":"CP Bradney","year":"2002","journal-title":"J Virol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.157.1.462","article-title":"Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4\/V3 peptide T1SP10 MN(A).","volume":"157","author":"HF Staats","year":"1996","journal-title":"J Immunol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.4049\/jimmunol.174.4.2190","article-title":"A novel neurotoxoid vaccine prevents mucosal botulism.","volume":"174","author":"R Kobayashi","year":"2005","journal-title":"J Immunol"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.08.006","article-title":"Effective induction of protective systemic immunity with nasally-administered vaccines adjuvanted with IL-1.","author":"WM Gwinn","year":"2010"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1016\/j.vaccine.2004.03.011","article-title":"A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.","volume":"22","author":"MA Egan","year":"2004","journal-title":"Vaccine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.","volume":"3","author":"J Huang","year":"2007","journal-title":"Hum Vaccines"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.vaccine.2008.12.013","article-title":"Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.","volume":"27","author":"D Coucke","year":"2009","journal-title":"Vaccine"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen.","volume":"170","author":"PN Boyaka","year":"2003","journal-title":"J Immunol"},{"key":"ref64","article-title":"Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.","author":"PL Moro","year":"2010"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"e13755","DOI":"10.1371\/journal.pone.0013755","article-title":"Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.","volume":"5","author":"RM Mallory","year":"2010","journal-title":"PLoS ONE"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.vaccine.2009.09.092","article-title":"Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.","volume":"28","author":"PJ De Villiers","year":"2009","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i1.20","article-title":"Drug delivery to the nasal cavity: in vitro and in vivo assessment.","volume":"21","author":"SP Newman","year":"2004","journal-title":"Critical Reviews in Therapeutic Drug Carrier Systems"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.bioeng.10.061807.160544","article-title":"Targeted drug-aerosol delivery in the human respiratory system.","volume":"10","author":"C Kleinstreuer","year":"2008","journal-title":"Annu Rev Biomed Eng"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0016532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:26:39Z","timestamp":1685924799000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0016532"}},"subtitle":[],"editor":[{"given":"George","family":"Deepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0016532","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}